Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

3,832

Participants

Timeline

Start Date

May 2, 2025

Primary Completion Date

May 2, 2032

Study Completion Date

May 2, 2035

Conditions
Breast Cancer
Interventions
DRUG

Letrozole

Letrozole 2.5 mg daily

DRUG

Anastrozole

Anastrozole 1 mg daily

DRUG

Exemestane

Exemestane 25 mg daily

DRUG

Tamoxifen

Tamoxifen 20 mg daily

Trial Locations (15)

Unknown

Visby Hospital, Visby

General Hospital of Eskilstuna, Eskilstuna

Falun County Hospital, Falun

Gävle Hospital, Gävle

Sahlgrenska University Hospital, Gothenburg

Ryhov County Hospital, Jönköping

Kalmar Hospital, Kalmar

Lund University Hospital, Lund

Örebro University Hospital, Örebro

Karolinska University Hospital, Stockholm

St Göran Capio Hospital, Stockholm

University Hospital of Umeå, Umeå

Akademiska University Hospital Uppsala, Uppsala

Växjö Hospital, Vaxjo

Västerås General Hospital, Västerås

All Listed Sponsors
collaborator

Mid-Sweden Regional Cancer Centre

UNKNOWN

collaborator

Akademiska University Hospital, Uppsala, Sweden

UNKNOWN

lead

Region Örebro County

OTHER